HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study
1 clinical trials · Condition
◉ Watch HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study
| Record | Firm | Date |
|---|---|---|
| Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study) (NCT04817540) | Gangnam Severance Hospital | 2021-09-01 |
Track HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study automatically
Every clearance here is in the API, with alerts when new ones post.